HC Wainwright Reiterates Buy Rating for Nuvectis Pharma
Analyst Joseph Pantginis maintains a buy rating on Nuvectis Pharma with a $39 target, a 51.75% upside from the current price.
Key Points
- HC Wainwright's Joseph Pantginis reiterated a buy rating on Nuvectis Pharma, Inc. (NVCT) with a $39 price target on June 22, 2026.
- HC Wainwright's $39 price target implies 51.75% upside from Nuvectis Pharma, Inc.'s ($NVCT) current $25.70 share price.
- Nuvectis Pharma is a clinical-stage biotech company with a market cap of $366.6 million and a 52-week range of $5.55 to $14.16.
- Recent insider buying included Kenneth Hoberman and others, each acquiring 35,000 shares on June 11, 2026.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
HC Wainwright & Co.'s analyst Joseph Pantginis has reiterated a buy rating on Nuvectis Pharma, Inc. (NasdaqCM: NVCT) as of June 22, 2026. The firm set a price target of $39 for the biopharmaceutical company, which is currently developing precision medicines for oncology.
HC Wainwright & Co. vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Other Institutional Activity in Nuvectis Pharma
BlackRock, Inc. trimmed its holdings by 18,364 shares, ending with 764,441 shares valued at about $5.91 million. Vanguard Capital Management LLC opened a new position with 659,879 shares worth $5.10 million. Iridian Asset Management LLC/CT increased its stake by 65,437 shares to hold 651,757 shares valued at approximately $5.04 million. Occam Crest Management LP added 27,147 shares, totaling 407,147 shares valued at $3.15 million. Geode Capital Management, LLC grew its position by 20,081 shares to 384,105 shares, worth about $2.97 million.
Nuvectis Pharma, Inc. Stock Up 8.3%
Shares of Nuvectis Pharma traded near $13.54 on Monday. The company has a market cap of $366.6 million and is not currently profitable, as indicated by its negative forward P/E ratio of -14.4. The stock's 52-week low is $5.55, while its high is $14.16. The 50-day moving average is $9.89, and the 200-day moving average is $7.99. Nuvectis has a current ratio of 2.27 and a quick ratio of 2.25.
$NVCT price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Insider Buying and Selling at Nuvectis Pharma, Inc.
On June 11, 2026, several insiders, including Kenneth Hoberman, James Oliviero III, Matthew Kaplan, and Juan Sanchez, each purchased 35,000 shares. Additionally, Shay Shemesh, the Chief Development and Operations Officer, and Ron Bentsur, the Chairman and CEO, each acquired 150,000 shares on January 6, 2026.
Analysts Set New Price Targets
On June 22, 2026, HC Wainwright & Co. maintained its buy rating on Nuvectis Pharma with a $39 price target. Overall, the company has a strong buy consensus with a mean target price of $17.4 based on five analyst opinions.
About Nuvectis Pharma
Nuvectis Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing precision medicines for treating serious oncology conditions. Based in Fort Lee, New Jersey, the company is working on NXP900, a drug candidate targeting solid tumors. Founded in 2020, Nuvectis is led by CEO Ron Bentsur and employs 12 people.
Bottom Line
HC Wainwright's reiteration of a buy rating signals confidence in Nuvectis Pharma's prospects, with a significant price target set at $39. As a clinical-stage company, Nuvectis is developing innovative treatments in oncology, drawing interest from institutional investors and analysts alike. Investors should note that analyst ratings are forward-looking and reflect expectations based on current data.
Get Nuvectis Pharma, Inc. alerts
New 13F filings, insider trades, and analyst moves on $NVCT, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.